While immune checkpoint blockade leads to potent antitumor efficacy, it also leads to immune-related adverse events in cancer patients. These toxicities stem from systemic immune activation resulting in inflammation of multiple organs, including the gastrointestinal tract, lung, and endocrine organs. We developed a dual variable domain immunoglobulin of anti-CTLA4 antibody (anti-CTLA4 DVD, where CTLA4 is defined as cytotoxic T lymphocyte–associated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield the inner anti-CTLA4–binding domain. Upon reaching the tumor, the outer domain was cleaved by membrane type-serine protease 1 (MT-SP1) present in the tumor microenvironment, leading to enhanced localization of CTLA4 blockade. Anti-CTLA4 DVD markedly reduced multiorgan immune toxicity by preserving tissue-resident Tregs in Rag 1–/– mice that received naive donor CD4+ T cells from WT C57BL/6j mice. Moreover, anti-CTLA4 DVD induced potent antitumor effects by decreasing tumor-infiltrating Tregs and increasing the infiltration of antigen-specific CD8+ T lymphocytes in TRAMP-C2–bearing C57BL/6j mice. Treg depletion was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanism, as anti-CTLA4 without the FcγR-binding portion (anti-CTLA4 DANA) spared Tregs, preventing treatment-induced toxicities. In summary, our results demonstrate an approach to anti-CTLA4 blockade that depletes tumor-infiltrating, but not tissue-resident, Tregs, preserving antitumor effects while minimizing toxicity. Thus, our tumor-conditional anti-CTLA4 DVD provides an avenue for uncoupling antitumor efficacy from immunotherapy-induced toxicities.
Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, Michael Evans, Junnian Wei, Yung-hua Wang, Mingyi Chen, John Huang, Chanhyuk Park, Anthony Chang, Jiaxi Wang, Susan Westmoreland, Christine Beam, Dave Banach, Diana Bowley, Feng Dong, Jane Seagal, Wendy Ritacco, Paul L. Richardson, Soumya Mitra, Grace Lynch, Pete Bousquet, John Mankovich, Gillian Kingsbury, Lawrence Fong
Title and authors | Publication | Year |
---|---|---|
Targeting the spectrum of immune checkpoints in prostate cancer
LA Sena, SR Denmeade, ES Antonarakis |
Expert Review of Clinical Pharmacology | 2021 |
Generation of vascular chimerism within donor organs
S Cohen, S Partouche, M Gurevich, V Tennak, V Mezhybovsky, D Azarov, S Soffer-Hirschberg, B Hovav, H Niv-Drori, C Weiss, A Borovich, G Cohen, A Wertheimer, G Shukrun, M Israeli, V Yahalom, D Leshem-Lev, L Perl, R Kornowski, A Wiznitzer, A Tobar, M Feinmesser, E Mor, E Atar, E Nesher |
Scientific Reports | 2021 |
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
N Sobhani, DR Tardiel-Cyril, A Davtyan, D Generali, R Roudi, Y Li |
Cancers | 2021 |
In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET
N Zhao, C Bardine, AL Lourenço, Y Wang, Y Huang, SJ Cleary, DM Wilson, DY Oh, L Fong, MR Looney, MJ Evans, CS Craik |
ACS Central Science | 2021 |
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
J Guo, Y Liang, D Xue, J Shen, Y Cai, J Zhu, YX Fu, H Peng |
Cell Research | 2021 |
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
X Cai, H Zhan, Y Ye, J Yang, M Zhang, J Li, Y Zhuang |
Frontiers in Genetics | 2021 |
Immune-Related Genes to Construct a Novel Prognostic Model of Breast Cancer: A Chemosensitivity-Based Study
ZM Deng, W Hu, FF Dai, MQ Yuan, M Hu, YX Cheng |
Frontiers in immunology | 2021 |
Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies
J Cao, M Zhang, B Wang, L Zhang, F Zhou, M Fang |
Frontiers in Oncology | 2021 |
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
X Cao, Y Liang, Z Hu, H Li, J Yang, EJ Hsu, J Zhu, J Zhou, YX Fu |
Nature Communications | 2021 |
Switchable immune modulator for tumor-specific activation of anticancer immunity
Y Zhao, YQ Xie, SV Herck, S Nassiri, M Gao, Y Guo, L Tang |
Science Advances | 2021 |
Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response
L Jacobs, L Yshii, S Junius, N Geukens, A Liston, K Hollevoet, P Declerck |
Cancer Gene Therapy | 2021 |